Category News

Merck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer

Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940 (mRNA-4157), an individualized neoantigen therapy (INT), combined with KEYTRUDA® (pembrolizumab),…

Read MoreMerck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer

WuXi Biologics Introduces WuXia™ RidGS Platform for Antibiotic-Free Cell Line Development

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched WuXia™ RidGS, an advanced glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. Designed for antibiotic-free cell line development, this platform utilizes zinc finger…

Read MoreWuXi Biologics Introduces WuXia™ RidGS Platform for Antibiotic-Free Cell Line Development

Judo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney

Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA conjugates via megalin receptors. This mechanism enables targeted gene knockdown…

Read MoreJudo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney

Novartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial

Novartis presented promising 12-month results from its Phase III APPEAR-C3G study at the 2024 American Society of Nephrology (ASN) Kidney Week. These findings show that patients with C3 glomerulopathy (C3G) who received oral Fabhalta® (iptacopan) alongside supportive care maintained clinically…

Read MoreNovartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial